Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.14670/HH-18-700
Twittear
Título: | Elevated tissue expression of RANKL and RANK is associated with poorer survival rates in pancreatic cancer patients |
Fecha de publicación: | 2024 |
Editorial: | Universidad de Murcia, Departamento de Biologia Celular e Histiologia |
Cita bibliográfica: | Histology and Histopathology Vol. 39, nº9 (2024) |
ISSN: | 0213-3911 1699-5848 |
Materias relacionadas: | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología |
Palabras clave: | Pancreatic adenocarcinoma Receptor activator of nuclear factor-kappa B (RANK) Receptor activator of nuclear factor-kappa B ligand (RANKL) Cancer survival Prognostic biomarkers |
Resumen: | Pancreatic cancer is a highly lethal malignancy with a growing incidence reported worldwide. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, which is often diagnosed at advanced stages, making its prognosis and medical management difficult. The identification of histopathological biomarkers has allowed a more precise stratification of pancreatic cancer patients, providing additional information about their prognosis and offering possible therapeutic targets to be explored. The prognostic value of the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL) has been evaluated in breast and prostate tumors, however, their usefulness has not been assessed in pancreatic cancer. In the present work, we analyzed the relationship between the protein expression of RANK and RANKL with the survival of 41 patients with pancreatic cancer followed for 60 months, by performing immunohisto-chemistry and Kaplan-Meier curves. Our results demonstrate a direct association of high expression levels of RANK and RANKL with poorer survival of pancreatic cancer patients in comparison to those with low/medium and null expression levels of both markers. Further studies should be conducted to explore the carcinogenic role of both components in this type of tumor, as well as additional promising translational uses. |
Autor/es principal/es: | Ortega, Miguel A Jiménez Álvarez, Laura Fraile Martinez, Oscar Garcia Montero, Cielo Leon Oliva, Diego De Toledo Lobo, M. Val Palacios, Esther Granado, Paula Esteban, Alfonso Guijarro, Luis G. Pekarek, Leonel Asúnsolo, Ángel López González, Laura Buján, Julia García Honduvilla, Natalio Álvarez Mon, Melchor Saez, Miguel A Díaz Pedrero, Raúl |
URI: | http://hdl.handle.net/10201/143578 |
DOI: | https://doi.org/10.14670/HH-18-700 |
Tipo de documento: | info:eu-repo/semantics/article |
Número páginas / Extensión: | 8 |
Derechos: | info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Aparece en las colecciones: | Vol.39, nº9 (2024) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Ortega-39-1133-1140-2024.pdf | 619,34 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons